Physician

Charles Wayne Bryan, M.D.

According to 2025 Medicare claims, Charles Bryan, M.D. (NPI: 1831189877) practices hematology/oncology in the Asheville, NC market, with the plurality of this provider's patient population coming from Buncombe, NC. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 28806-2316. Bryan is affiliated with the Mission Health Partners, LLC (ACO ID: A2591) and AdvantagePoint Health Alliance - Western North Carolina, LLC (ACO ID: A5039), participating under the MSSP model.

Bryan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,047 traditional Medicare patients, billed 140,393 HCPCS/CPT codes, and received $2,755,186 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,596 prescription claims across 265 beneficiaries totaling $4,409,375 in drug costs, led by Revlimid (Lenalidomide). DME data shows 35 claims. Open Payments data shows 25 records totaling $682. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $120,377 to $2,755,186. Similarly, Part D prescription costs have moved sharply higher in recent years, from $893,112 to $4,409,375. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $11,681 to $1,139.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	693	4,794	$120,377
2016	686	3,969	$105,648
2017	597	1,343	$80,191
2018	553	1,196	$80,141
2019	515	1,061	$70,857
2020	703	83,777	$1,803,469
2021	721	91,409	$2,137,598
2022	804	115,654	$2,186,934
2023	1,000	115,681	$2,048,742
2024	1,047	140,393	$2,755,186

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	233	1,338	$893,112
2016	228	1,174	$1,041,093
2017	233	1,123	$1,416,253
2018	230	1,238	$1,809,896
2019	232	1,042	$1,513,358
2020	207	1,138	$2,053,917
2021	215	1,183	$2,171,174
2022	225	1,225	$2,924,239
2023	236	1,352	$3,416,915
2024	265	1,596	$4,409,375

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	126	$11,018
2016	N/R	24	$2,179
2017	N/R	16	$8,642
2018	N/R	54	$4,646
2019	N/R	33	$1,995
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	50	$1,594
2023	N/R	48	$8,987
2024	N/R	35	$769

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	174	432	$91
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	379	713	$88
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	322	471	$12
36415	Insertion of needle into vein for collection of blood sample	636	1,220	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	646	1,369	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	66	1,722	$1,043,541
Tagrisso	Osimertinib Mesylate	23	690	$348,323
Xtandi	Enzalutamide	37	1,110	$341,751
Ibrance	Palbociclib	20	553	$308,301
Jakafi	Ruxolitinib Phosphate	12	360	$303,915

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	18	$468
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	17	$301

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	25	$682	JAZZ PHARMACEUTICALS INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Charles Wayne Bryan, M.D.?

Tedicare shows public-source Medicare data for Charles Wayne Bryan, M.D. (NPI 1831189877), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Charles Wayne Bryan, M.D. have ACO affiliation data?

Charles Wayne Bryan, M.D. is shown with ACO affiliation data for Mission Health Partners, LLC (MSSP, ACO ID A2591) and AdvantagePoint Health Alliance - Western North Carolina, LLC (MSSP, ACO ID A5039).

What billing organization is linked to Charles Wayne Bryan, M.D.?

Charles Wayne Bryan, M.D. is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Charles Wayne Bryan, M.D. have Open Payments data?

Charles Wayne Bryan, M.D. has 25 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.